7780 — Daiken Biomedical Co Cashflow Statement
0.000.00%
Last trade - 00:00- TWD15.11bn
- TWD9.96bn
- TWD1.90bn
Annual cashflow statement for Daiken Biomedical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | — | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | 110 | 195 | 140 | 417 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 0.987 | 0.493 | -21.5 | -32.3 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | -69 | -91.6 | -70.5 | -120 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | 41.6 | 105 | 51.8 | 273 |
| Capital Expenditures | -0.053 | — | -1.25 | -0.385 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -31.9 | -62 | 85.3 | -3,035 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Change in Net Intangibles | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -32 | -62 | 84.1 | -3,035 |
| Financing Cash Flow Items | — | -140 | — | — |
| Other Financing Cash Flow | ||||
| Total Cash Dividends Paid | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 136 | 0.117 | 718 | 3,820 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 146 | 43.4 | 853 | 1,097 |